Senti Biosciences Reports $61.4M 2025 Net Loss, Positive AML Data with RMAT
Senti Biosciences ended 2025 with $16.4 million in cash, R&D spend of $37.6 million, G&A costs of $26.2 million and a $61.4 million net loss ($2.73 per share). The company also reported positive preliminary Phase 1 SENTI-202 AML data and secured RMAT designation.
1. 2025 Financial Performance
Senti Biosciences closed the year with cash and equivalents of $16.4 million. Research and development expenses totaled $37.6 million, general and administrative costs were $26.2 million, and net loss reached $61.4 million, or $2.73 per share, including a $5.1 million asset impairment and $5.7 million in non-cash stock compensation.
2. Phase 1 SENTI-202 Results
The ongoing Phase 1 trial of SENTI-202 in relapsed/refractory acute myeloid leukemia demonstrated encouraging response rates, durable remissions and a favorable safety profile. These preliminary data reinforce the potential of the Gene Circuit–engineered cell therapy to deliver targeted cancer cell eradication while sparing healthy tissue.
3. RMAT Designation and Platform Advances
The FDA granted Regenerative Medicine Advanced Therapy designation for SENTI-202 in adults with relapsed or refractory AML, accelerating regulatory interactions. Senti continues to expand and refine its proprietary Gene Circuit platform across multiple cell therapy programs while maintaining disciplined capital management to support upcoming development milestones.